Positive phase III results for Roche ’s Hemlibra for haemophilia A without factor VIII inhibitors published in New England Journal of Medicine

Roche today announced that pivotal data from the phase III HAVEN 3 study, which evaluated Hemlibra ® (emicizumab) prophylaxis administered every week or every two weeks in adults and adolescents aged 12 years or older with haemophilia A without factor VIII inhibitors, were published in the 30 August 2018 issue of the New England Journal of Medicine (NEJM).
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news